- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.12.24 | ABVC BioPharma gets $200K in cash from OncoX BioPharma | 1 | Seeking Alpha | ||
| 11.12.24 | ABVC BioPharma, Inc.: ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners | 2 | GlobeNewswire (USA) | ||
| ABVC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 14.11.24 | ABVC BioPharma GAAP EPS of -$0.02, revenue of $0.38M | 1 | Seeking Alpha | ||
| 14.11.24 | ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones | 115 | GlobeNewswire (Europe) | ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could... ► Artikel lesen | |
| 14.11.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11.24 | ABVC BIOPHARMA, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | - | SEC Filings | ||
| 22.10.24 | ABVC BioPharma sichert sich zusätzliche Lizenzgebühren | 3 | Investing.com Deutsch | ||
| 22.10.24 | ABVC BioPharma secures additional licensing fees | 1 | Investing.com | ||
| 22.10.24 | ABVC BioPharma, Inc.: ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners | 73 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous... ► Artikel lesen | |
| 19.10.24 | ABVC BioPharma switches to new independent accounting firm | 1 | Investing.com | ||
| 19.10.24 | ABVC BioPharma wechselt zu neuer unabhängiger Wirtschaftsprüfungsgesellschaft | 1 | Investing.com Deutsch | ||
| 18.10.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.08.24 | ABVC BioPharma GAAP EPS of -$0.09 | 1 | Seeking Alpha | ||
| 15.08.24 | ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements | 176 | GlobeNewswire (Europe) | • Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained... ► Artikel lesen | |
| 15.08.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08.24 | ABVC BIOPHARMA, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 18.04.24 | ABVC BioPharma, Inc.: AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share | 311 | GlobeNewswire (Europe) | FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,320 | -3,30 % | Nanorepro: "Bedeutender Schritt für die Zukunft" | Nanorepro kommt 2024 auf einen Umsatz von 4,4 Millionen Euro (Vorjahr: 3,2 Millionen Euro). Mit Corona-Tests, dem Umsatztreiber in früheren Jahren, werden dabei nur noch marginale Umsätze erzielt. Vor... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,790 | +0,77 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| BIOXXMED | 0,982 | -9,07 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei bioXXmed, Deutsche Wohnen, fox e-mobility, Linus Digital, ThyssenKrupp, Vonovia | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| ORGANOVO | 0,311 | -2,97 % | Organovo, Inc.: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer | SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease... ► Artikel lesen | |
| OCUGEN | 0,703 | -1,26 % | Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa | MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,038 | 0,00 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| BIO-GATE | 0,765 | -2,55 % | Bio-Gate: Prognose reduziert, Potenzial aber weiter hoch | Nach Darstellung von SMC-Research musste Bio-Gate wegen Auftragsverschiebungen die Jahresprognose für 2024 reduzieren. SMC-Analyst Holger Steffen sieht immer noch hohes Potenzial in dem Geschäft, aber... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | TREVENA INC - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,750 | 0,00 % | Best of BioTech 2025 - BioNTech, Bayer, Pfizer, BioNxt, Defence Therapeutics, Evotec und Vidac Pharma | Die biotechnologische Forschung wird 2025 von mehreren maßgeblichen Trends, Technologien und gesellschaftlichen Herausforderungen geprägt sein. Unter Einsatz von Wissen und Geld verspricht sich die... ► Artikel lesen | |
| VAXART | 0,653 | -4,88 % | Vaxart, Inc.: Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial | Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the... ► Artikel lesen | |
| REDHILL BIOPHARMA | 5,900 | 0,00 % | RedHill Biopharma Ltd.: RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer | The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,060 | +4,51 % | Burcon NutraScience Corporation: Burcon Agrees to Terms with its Alliance Partner for a Protein Production Facility | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| AFFIMED | 0,974 | +1,04 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| IMMUNIC | 0,936 | +2,86 % | EQS-News: Immunic AG: Immunic to Participate in Investor and Scientific Conferences in February | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor and Scientific Conferences in February
04.02.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,177 | +2,31 % | AIM ImmunoTech Inc. - S-1/A, General form for registration of securities |
Das Unternehmen ABVC BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,485 Euro und damit -4,53 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABVC BIOPHARMA INC finden Sie auf Wallstreet Online.
